Clinical indications

Neurodegenerative disorders represent an enormous and ever increasing disease burden in modern society. The Alzheimer’s Association estimates the annual cost of providing care for Alzheimer’s patients in the United States at $200 billion in 2012. In Europe, brain disorders with associated cognitive problems account for over one third of the burden of all diseases.

The absence of effective clinical biomarkers has been the key limiting factor in the development both of early stage diagnostics and effective remedies for any of the major groups of CNS disorders such as Alzheimer’s disease and Parkinson’s disease.